Is there a role for assessing measurable/minimal residual disease (MRD) in multiple myeloma at this time?
1
1 Answers
Mednet Member
Medical Oncology · Winship Cancer Institute of Emory University
MRD assessment in myeloma is challenging. The EuroFlow standard and Adaptive ClonoSEQ technologies seem to be winning out for the moment, but the Mayo Clinic mass spectrometry peripheral blood assay may be the next generation. The advantage of the flow-cytometry based assay is that it involves live ...